Tenon Medical, Inc.
Tenon Medical develops and sells medical devices for surgical treatment of sacroiliac joint disorders associated with lower back pain. Its products are used by physicians performing spine and pelvic surgery, and the company focuses on the U.S. market. Tenon’s portfolio includes the Catamaran SI Joint Fusion System, which uses a single titanium implant and an inferior-posterior approach, and the SImmetry+ SI Joint Fusion System, which uses minimally invasive lateral access, joint preparation, bone grafting and titanium implants. Tenon markets and sells the systems primarily through independent distributors and sales representatives specializing in orthopedics and spine. Healthcare facilities purchase the products for use in procedures; facilities and clinicians separately submit reimbursement claims to insurers. Tenon is headquartered in Los Gatos, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TNON in the last 30 days.
See all $TNON insider activity →Tenon Medical (TNON) reported Q3 2026 revenue of $1.4M, up 22% YoY, with gross profit of $1.0M (66.3% margin). The company raised $15.6M, repaid convertible notes, and ended the quarter with $8.3M in cash. It launched a 3D-printed lateral screw and added 8 new U.S. patents.
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenon ® Medical Reports Third Quarter 2026 Financial Results ~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~ ~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~ ~ Raised Ap
Tenon Medical (TNON) will report Q3'26 earnings on November 12. Analysts expect revenue of 1.55M USD and an EPS of (4.22) USD. The results will be announced after market close at 4:05 PM ET.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning TNON (Tenon Medical, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 4 bearish.
Recent TNON coverage spans earnings, corporate actions and financial news.
Quarterly earnings release for a micro‑cap medical device company.
Earnings beat on revenue growth and balance sheet strengthening may support modest price appreciation.
Guidance shows very low revenue and a loss per share, suggesting pressure on the stock.
The scheduled earnings release and analyst Q&A create a near-term catalyst window for TNON positioning and volatility into Nov. 12.
The successful alpha tests may boost investor confidence in Tenon's product pipeline and drive short-term buying pressure.
AlphAI scores every news story that mentions TNON with an AI model for sentiment and relevance, and aggregates insider trades from Tenon Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenon Medical (TNON) reported Q3 2026 revenue of $1.4M, up 22% YoY, with gross profit of $1.0M (66.3% margin). The company raised $15.6M, repaid convertible notes, and ended the quarter with $8.3M in cash. It launched a 3D-printed lateral screw and added 8 new U.S. patents.
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenon ® Medical Reports Third Quarter 2026 Financial Results ~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~ ~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~ ~ Raised Ap
Tenon Medical (TNON) will report Q3'26 earnings on November 12. Analysts expect revenue of 1.55M USD and an EPS of (4.22) USD. The results will be announced after market close at 4:05 PM ET.
Tenon Medical (NASDAQ:TNON) will release Q3 2026 financial results on Nov. 12, 2026, followed by a conference call and Q&A with analysts. The company specializes in sacro-pelvic disorder treatments and offers two SI Joint Fusion Systems. The call details and replay information are provided.
Tenon Medical (TNON) completed initial tests of its Quickstep Decorticator, a surgical device for sacroiliac joint fusion procedures. The company plans a full market release in Q1 2027. The device is part of the SImmetry+ SI Joint Fusion System, which received a full market launch earlier this year. The Quickstep Decorticator allows surgeons to drill and decorticate the joint through a single instrument, reducing the need for multiple tools.
Tenon Medical (TNON) secured waivers from an institutional investor and WallachBeth Capital to increase shares in its at-the-market offering. In exchange, TNON issued a warrant for 125,000 shares at $5.02, expiring in 2031, and agreed to register shares for resale. The waivers support the planned offering increase, with certain restrictions extended by 15 days.
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on August 27, 2026, Tenon Medical, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Inve
Tenon Medical (TNON) launched its SImmetry+ SI Joint Fusion System after a successful alpha phase that generated $1.2M in revenue. The company plans to expand inventory to meet demand and expects more product launches. Physicians reported positive feedback on the system's design and effectiveness.
Tenon Medical (NASDAQ:TNON) launched its SImmetry+ SI Joint Fusion System, generating $1.2M in revenue during its alpha phase. The company plans to expand inventory to meet demand and expects more product launches. The system received positive physician feedback and aims to address a broader range of patient anatomies. Tenon believes this platform will drive growth and solidify its market position.
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338 LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming
